According to Halozyme Therapeutics's latest financial reports the company's total debt is $1.50 Billion USD. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2024-12-31 | $1.50 B | 0.44% |
2023-12-31 | $1.49 B | -0.45% |
2022-12-31 | $1.50 B | 71.8% |
2021-12-31 | $0.87 B | 120.7% |
2020-12-31 | $0.39 B | -1.33% |
2019-12-31 | $0.40 B | 218.55% |
2018-12-31 | $0.12 B | -37.54% |
2017-12-31 | $0.20 B | -6.59% |
2016-12-31 | $0.21 B | 334.69% |
2015-12-31 | $49.83 M | -0.05% |
2014-12-31 | $49.86 M | 0.18% |
2013-12-31 | $49.77 M | 59.98% |
2012-12-31 | $31.11 M | |
2011-12-31 | N/A |
Company | Total debt/th> | differencediff. | Country |
---|---|---|---|
![]() MannKind Corp MNKD | $47.25 M | -96.87% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $38.51 B | 2,455.04% | ๐บ๐ธ USA |
![]() Baxter BAX | $10.30 B | 583.87% | ๐บ๐ธ USA |
![]() Pfizer PFE | $61.29 B | 3,965.87% | ๐บ๐ธ USA |
![]() Sanofi SNY | $22.78 B | 1,411.23% | ๐ซ๐ท France |
![]() Johnson & Johnson JNJ | $52.25 B | 3,366.25% | ๐บ๐ธ USA |